Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lipsome sorts itself out

Noteworthy

The Liposome Co. Inc. responded to the failure of its Ventus C-53 liposomal prostaglandin in acute respiratory distress syndrome by announcing a restructuring designed to focus the company on its oncology programs.

On the heels of the Ventus setback in a Phase III trial (see BioCentury Extra June 26), the restructuring announced last week will cut 130-135 positions - 110 of which are filled -

Read the full 661 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE